AbbVie offers a strong bullish outlook with rising earnings, dividends, and technical signals. Read here for an analysis of ...

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio ...

But some Dividend Kings are better than others. Here's my favorite Dividend King to buy in November.

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...

Pharmaceutical stocks are getting more attention these days as the global drug market is expected to reach $1.21 trillion in ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F.

UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM ESTCompany ParticipantsMeenal Sethna - Executive VP ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Rinvoq brought in revenue of $5.97 billion in 2024, equating to about half of AbbVie’s total top-line figure, while the company expects the drug and Skyrizi to rake in a combined $31 billion in 2027.